The EU CHMP Agency Recommended Approval of TG Therapeutics Firm’s BRIUMVI™ for Relapsing Forms of MS in Adults

TG Therapeutics
TG Therapeutics, Inc. (TGTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of BRIUMVITM (ublituximab-xiiy) for the treatment of adult patients relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.